Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Replicative Cell Senescence

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...

Replicative Cell Senescence

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Universal transcriptomic hallmarks of mammalian ageing and mortality.

Nature·2026

Same author

Dynamics of genetic and somatic trade-offs in ageing and mortality.

Nature·2026

Same author

Exon-Skipping Antisense Oligonucleotides for H3.3K27M-Altered Diffuse Midline Glioma Therapy.

bioRxiv : the preprint server for biology·2026

Same author

Patient-derived organoid xenografts reveal the multifaceted role of the lncRNA <i>MALAT1</i> in breast cancer progression.

bioRxiv : the preprint server for biology·2026

Same author

Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice.

GeroScience·2026

Same author

Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: May 22, 2026

A Suppressor Screen for the Characterization of Genetic Links Regulating Chronological Lifespan in Saccharomyces cerevisiae

A Suppressor Screen for the Characterization of Genetic Links Regulating Chronological Lifespan in Saccharomyces cerevisiae

Published on: September 17, 2020

Rapamycin slows aging in mice.

John E Wilkinson¹, Lisa Burmeister, Susan V Brooks

¹Unit for Laboratory Animal Medicine and Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.

|May 17, 2012

Summary

This summary is machine-generated.

Rapamycin extends lifespan in mice by slowing multiple aging aspects, not just preventing cancer. However, it also causes harmful side effects like testicular degeneration and cataracts.

More Related Videos

Measuring Replicative Life Span in the Budding Yeast

Measuring Replicative Life Span in the Budding Yeast

Published on: June 25, 2009

Measuring Caenorhabditis elegans Life Span in 96 Well Microtiter Plates

Measuring Caenorhabditis elegans Life Span in 96 Well Microtiter Plates

Published on: March 18, 2011

Related Experiment Videos

Last Updated: May 22, 2026

A Suppressor Screen for the Characterization of Genetic Links Regulating Chronological Lifespan in Saccharomyces cerevisiae

A Suppressor Screen for the Characterization of Genetic Links Regulating Chronological Lifespan in Saccharomyces cerevisiae

Published on: September 17, 2020

Measuring Replicative Life Span in the Budding Yeast

Measuring Replicative Life Span in the Budding Yeast

Published on: June 25, 2009

Measuring Caenorhabditis elegans Life Span in 96 Well Microtiter Plates

Measuring Caenorhabditis elegans Life Span in 96 Well Microtiter Plates

Published on: March 18, 2011

Area of Science:

Gerontology and pharmacology
Molecular biology and aging research

Background:

Rapamycin is known to increase lifespan in mice.
Its precise mechanism, whether solely through anti-cancer effects or broader anti-aging properties, remains under investigation.

Purpose of the Study:

To investigate if rapamycin slows multiple aging processes in mice beyond its effects on neoplastic diseases.
To identify potential adverse effects of rapamycin treatment on aging-related changes.

Main Methods:

Treatment of mice with rapamycin starting at 9 months of age.
Assessment of age-dependent changes in various tissues (heart, liver, adrenal glands, endometrium, tendon) and spontaneous activity.
Evaluation of the incidence of neoplastic diseases, testicular degeneration, and cataracts.

Main Results:

Rapamycin treatment significantly slowed age-dependent changes in multiple organs and spontaneous activity.
These effects suggest rapamycin retards multiple aspects of aging in mice.
However, rapamycin treatment also led to a higher incidence of testicular degeneration and cataracts.

Conclusions:

Rapamycin demonstrates broad anti-aging effects in mice, impacting various physiological systems.
The drug's potential therapeutic benefits must be weighed against adverse effects.
Further research is needed to optimize rapamycin's timing, dosage, and tissue-specific actions for clinical application, particularly concerning inhibitors of TOR (target of rapamycin) action.